Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old.
• People who have been diagnosed with a specific type of colon cancer called MSS colon adenocarcinoma, confirmed through laboratory testing (either genetic testing or tissue staining methods).
• People whose tumor is located less than 12cm from the anal opening, as measured by colonoscopy, MRI, or rectal ultrasound.
• People whose cancer imaging (MRI or rectal ultrasound) shows the tumor has grown to a certain depth into or through the bowel wall (stage T3–T4) or has spread to nearby lymph nodes (N+), but has not spread to other parts of the body (M0 on CT scan).
• People with a good general physical condition, rated 0 or 1 on a standard medical fitness scale (confirm with trial site).
• People with a life expectancy of more than one year.
• People who have been newly diagnosed, have not received any previous cancer treatment, and have no medical reasons preventing chemotherapy.
• People whose blood counts and organ function (including liver and kidney) meet specific healthy levels as defined by the trial (confirm with trial site for exact values).
• People who are willing and able to understand the study and provide written consent to participate.

Who may not be able to join:

• People with early-stage rectal cancer (T1–T2, no lymph node involvement, no spread), or people whose tumor is less than 5cm from the anal opening and classified as T4, where a specific type of major surgery (removal of the rectum and anus) would be needed.
• People with cancer occurring in multiple locations in the bowel at the same time.
• People whose tumor is causing a blockage, severe bleeding, or risk of bowel perforation that requires emergency surgery or a stent.
• People who are unable to tolerate chemotherapy or immunotherapy — for example, due to very low blood cell counts.
• People with a history of another cancer, except for certain low-risk cancers such as basal cell skin cancer, a specific type of thyroid cancer, or cancers that were entirely contained and not invasive.
• People experiencing a severe flare-up of a serious ongoing condition (such as lung disease, heart disease, or kidney problems) or a severe active infection (such as hepatitis, pneumonia, or heart inflammation), or those rated above 3 on a standard surgical risk scale (confirm with trial site).
• People with mental health conditions, inability to read, or communication difficulties that would prevent understanding of the study.
• People with existing nerve damage in their hands or feet that would prevent them from receiving a specific chemotherapy drug (oxaliplatin).
• People who have used steroid medications (glucocorticoids) continuously for more than 3 days in the month before signing the consent form, or who need ongoing steroid treatment for another condition.
• People who are unable to have a contrast-enhanced CT scan.
• People who are pregnant or breastfeeding.
• People who have declined to take part in the study.
• People whom the research team considers unsuitable for the study for other reasons.

Important: Always verify eligibility with the trial site directly before applying.